News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Submit a Press Release
Submit an Event
Search Query
Submit Search
Merck & Co.
NEWS
JOBS
IN THE PRESS
AWARDS
NEWS
Policy
Couple Accuses Merck & Co. Of Failing To Disclose Zostavax Vaccine Side Effects
November 18, 2016
·
1 min read
Deals
Unknown Buyer Backs Out Of Deal For Merck & Co.'s New Jersey Facility
November 18, 2016
·
1 min read
Job Trends
With Bristol-Myers Squibb, Genentech and Merck & Co. Expanding in the Bay Area, Some Wonder if the Real Estate Boom is Too Much
November 14, 2016
·
2 min read
Pharm Country
Why Investors Should Buy (and Avoid) Merck & Co.
November 11, 2016
·
2 min read
Deals
Why Merck & Co. and Allergan Won’t Buy Biogen
November 4, 2016
·
4 min read
Drug Development
Merck & Co.'s Alzheimer’s Contender Wows in Human Clinical Trial
November 3, 2016
·
3 min read
JOBS
Currently, there are no jobs for this company on BioSpace
Browse all jobs
here
Oops!
There was an issue retrieving the jobs list. Please reload the page to view more jobs.
Title
Location
Company Name
Desc
View details
IN THE PRESS
Press Releases
KEYTRUDA® (pembrolizumab) Plus WELIREG® (belzutifan) Given as Adjuvant Therapy Reduced the Risk of Disease Recurrence or Death by 28% Compared to KEYTRUDA Monotherapy in Certain Patients With Earlier-Stage Renal Cell Carcinoma (RCC)
March 2, 2026
·
19 min read
Press Releases
WELIREG® (belzutifan) Plus LENVIMA® (lenvatinib) Reduced the Risk of Disease Progression or Death by 30% Compared to Cabozantinib in Certain Previously Treated Patients With Advanced Renal Cell Carcinoma (RCC)
March 2, 2026
·
19 min read
Press Releases
KEYTRUDA® (pembrolizumab) Plus Paclitaxel With or Without Bevacizumab Significantly Improved Key Secondary Endpoint of Overall Survival (OS) Versus Paclitaxel With or Without Bevacizumab in Patients With Platinum-Resistant Recurrent Ovarian Cancer
March 2, 2026
·
19 min read
Press Releases
KEYTRUDA® (pembrolizumab) Plus Padcev® (enfortumab vedotin-ejfv) Reduced Risk of Event-Free Survival Events by 47% and Risk of Death by 35% for Cisplatin-Eligible Patients with Muscle-Invasive Bladder Cancer When Given Before and After Surgery
March 2, 2026
·
19 min read
Press Releases
Synthekine Announces Clinical Trial Collaboration with Merck to Evaluate STK-012 In Combination with Keytruda® (Pembrolizumab) and Chemotherapy in Ongoing Randomized Phase 2 Trial in First-Line, PD-L1 Negative Nonsquamous Non-Small Cell Lung Cancer
February 26, 2026
·
2 min read
Press Releases
FDA Approves NUMELVI™ (atinvicitinib tablets) for Dogs from Merck Animal Health – The First and Only Second-Generation Janus Kinase (JAK) Inhibitor for the Control of Pruritus Associated with Allergic Dermatitis
February 26, 2026
·
8 min read
Press Releases
Merck Announces Late-Breaking Data from Three Phase 3 Trials Evaluating Doravirine/Islatravir (DOR/ISL), an Investigational, Once-Daily, Two-Drug Regimen for the Treatment of Adults Living with HIV-1 at CROI 2026
February 26, 2026
·
19 min read
Press Releases
Oncology Market Set to Nearly Triple: Here Are Five Companies Leading the Charge
February 24, 2026
·
8 min read
Press Releases
Merck to Participate in the TD Cowen 46th Annual Health Care Conference
February 24, 2026
·
3 min read
Press Releases
Merck Evolves Human Health Operating Structure to Support Portfolio Execution
February 23, 2026
·
5 min read
